Get the Stockscreener App
20.32
3.75%
0.735
Schrodinger Inc stock is traded at $20.32, with a volume of 1.89M.
It is up +3.75% in the last 24 hours and down -10.78% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$19.58
Open:
$19.86
24h Volume:
1.89M
Relative Volume:
1.58
Market Cap:
$1.31B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-8.2918
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
+4.85%
1M Performance:
-10.78%
6M Performance:
-10.27%
1Y Performance:
+4.23%
1-Day Range:
$19.50
$20.45
1-Week Range:
$18.75
$20.45
52-Week Range:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
20.32 | 1.48B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
290.86 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
80.52 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
67.74 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.82 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.24 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrödinger Inc. May Be Forming Higher Low — Chartwatchers AlertJuly 2025 Patterns & Capital Efficient Trading Techniques - thegnnews.com
Schrödinger Inc. Stock Fails to Break Resistance Traders ReactJuly 2025 Sentiment & Smart Money Movement Tracker - newsyoung.net
Schrodinger discontinues SGR-2921 clinical development program - MSN
Schrödinger Stock Plummets After Halting Key Leukemia Drug Program - MSN
Schrodinger initiated with an Overweight at Barclays - MSN
Citi Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $20 - 富途牛牛
Schrodinger Inc Grants RSUs to New Employees Amidst Nasdaq Listing Rule Compliance. - AInvest
Is Schrödinger Inc.’s growth already priced inMarket Sentiment Review & Safe Entry Point Alerts - sundaytimes.kr
Schrödinger's Strategic Use of Equity Incentives to Drive Talent Retention and Long-Term Growth - AInvest
Schrödinger Discontinues Clinical Program After Two Patient Deaths - MSN
Schrodinger drops 16% as it abandons leukemia candidate - MSN
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Citigroup Downgrades Schrodinger from Buy to Neutral with Significant Price Target Reduction - AInvest
Schrödinger ends development of SGR-2921 after safety setback - The Pharma Letter
This Cisco Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern - Stocktwits
Schrodinger downgraded at Citi after clinical program exit - MSN
Schrodinger stock slips as Citi downgrades (SDGR:NASDAQ) - Seeking Alpha
Citigroup Downgrades Schrodinger to Neutral From Buy, Adjusts Price Target to $20 From $35 - MarketScreener
American Company "Schrödinger" Halts Development of Experimental Drug After Two Patient Deaths in Clinical Trial - tesaaworld.com
Schrodinger stock plunges after discontinuing key leukemia drug By Investing.com - Investing.com Canada
Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths - insights.citeline.com
Schrodinger Maintains Buy Rating from Craig-Hallum Despite Recent Hold Rating from TR | OpenAI. - AInvest
This AZZ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Schrödinger stops development of blood cancer therapy after two patient deaths - Reuters
Schrödinger Inc. Shows Early Signs of Technical StrengthInflation Watch & Short-Term High Return Ideas - beatles.ru
Schrödinger Inc. Reaches Critical Trendline SupportTake Profit & Reliable Breakout Stock Forecasts - newsyoung.net
Schrodinger stock plunges after discontinuing key leukemia drug - Investing.com
Schrödinger stock tumbles after discontinuing cancer drug program By Investing.com - Investing.com Australia
Schrödinger stock tumbles after discontinuing cancer drug program - Investing.com India
Barclays Raises PT to $110, Maintains Overweight Rating - AInvest
Sector Update: Health Care - MarketScreener
Schrodinger falls after ending blood cancer therapy development on patient deaths - TradingView
Schrodinger Plunges 19.23% After Halting SGR-2921 Program - AInvest
Schrodinger Discontinues SGR-2921 Program Following Deaths of Two AML Patients - MarketScreener
Schrodinger, Inc. Announces Discontinuation of Clinical Development Program for SGR-2921 - MarketScreener
Schrödinger Discontinues Clinical Program After Two Patient Deaths By Stocktwits - Investing.com India
Barclays Initiates Schrodinger at Overweight With $25 Price Target - MarketScreener
Schrödinger discontinues leukemia drug after patient deaths By Investing.com - Investing.com India
Schrödinger discontinues leukemia drug after patient deaths - Investing.com
Schrödinger Announces Discontinuation of SGR-2921 Program - Yahoo Finance
Barclays Initiates Schrodinger(SDGR.US) With Buy Rating, Announces Target Price $25 - 富途牛牛
Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts - Investing.com Nigeria
How Investors May Respond To Schrödinger (SDGR) Affirming 2025 Guidance Amid Revenue Growth and Narrowing Losses - simplywall.st
What makes Schrödinger Inc. stock price move sharplyQuick Doubling Picks Watch - newsyoung.net
Schrodinger, Inc. Earnings Call: Growth Amid Challenges - TipRanks
What risks could impact Schrödinger Inc. stock performanceMarket Opportunity Tracker for Swing Traders - Newser
Risk adjusted return profile for Schrödinger Inc. analyzedSecure Asset Flow and Trend Pattern Analysis - Newser
Using AI based signals to follow Schrödinger Inc.Strategy Playbook for Risk Controlled Trades - Newser
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Schrodinger Inc Stock (SDGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
1.72%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):